Successfully reported this slideshow.
Your SlideShare is downloading. ×

Press_Release_Pharmalagasy_CVO_Plus_Curatif_1633090235-1.pdf

More Related Content

Press_Release_Pharmalagasy_CVO_Plus_Curatif_1633090235-1.pdf

  1. 1. After evaluation of several criteria: cure, adverse events, biological results ... it has been concluded that: 70,45% of patients were cured as of 14 days. PROSPECTS 87,1% 70,45% EFFICACY These results represent a significant breakthrough in the fight against Covid-19. Madagascar with its CURATIVE CVO PLUS offers a complementary therapeutic tool to the existing arsenal against the pandemic in support of the vaccinal effort taken on a worldwide basis. Often qualified as a “bridge to the vaccine” this treatment entirely conceived and produced in Madagascar with local raw vegetal materials ambitions not only to provide support for lesser developed countries with low vaccinal coverage but also targets countries which are currently experiencing the limits of the mass vaccination strategy. Pharmalagasy and its partners are ready to commercialize CURATIVE CVO PLUS globally and currently has a 50 Million treatment per year capacity in Madagascar. Pharmalagasy and its partners also take this opportunity to thank the President of Madagascar Andry RAJOELINA for his vision and his support all along the project which has allowed within one short year to set up a flagship world level pharmaceutical factory, to elaborate the curative formulation for Covid-19 and also to finalize successful phase 3 clinical trials following Good Clinical Practice (GCP) A last and sincere thanks for the support provided by the World Health Organization (WHO) for having from the onset supervised the clinical trials of CURATIVE CVO PLUS. Holijaona RABOANA President of the Board of Directors PHARMALAGASY Pierre RAOELINA ANDRIAMBOLOLONA General Manager of PHARMALAGASY CURE CURATIVE CVO PLUS has an 87,1% efficacy rate for the treatment of Covid-19 for mild to moderate formsafter 28 days of monitoring. None of the patients under CURATIVE CVO PLUS have developpped a severe form of COVID-19 and all patients preserved their hepathic,renal and metabolic functions. PRESS RELEASE These results should have been confirmed in larger scale trials but it was concluded that a more adapted galenic form was needed for large scale distribution. It is to be noted that this phase 2 study was undertaken in the context of an international partnership involving Professor Dhanjay Jhurry Vice Chancellor of the University of Mauritius, Dr. Thomas Lodi Director of Integrative Oncology (Thailand) and Dr. Nathan Goodyear Oasis of Healing (Arizona U.S.) In oder to promote traditional Malagasy medicine and taking into account the availability in large scale of Artemisia annua and Ravintsara which are both produced locally in Madagascar, CURATIVE CVO PLUS – an improved traditional remedy- was formulated. The CVO PLUS CURATIVE gel caps contain a complex standardized extract of Artemisia annua and also the Ravintsara essential oil. Each gel cap is normalized in content of artemisinin at 150 mg, in flavonoid components at 3,3 mg, in terpenic compounds at 4mg and in eucalyptol at 7,1mg. Compared to raw plant material used in tea formulations (tambavy in Malagasy), the content of active principles is constant and stable. In order to evaluate the efficacy and the harmlessness of CURATIVE CVO PLUS in the treatment of Covid-19 a phase 3 clinical trial was undertaken between the months of January and May 2021. The clinical trial protocols were elaborated and supervised by the World Health Organization (WHO) which approved it before roll out. These clinical trials were then approved by the ethics committee of Malagasy biomedical research (CERBM) on December 17 2020 under the reference N° 073 MINSANP/SG/AGMED/CERBM. It was also officially registered on the Pan African Trial registry under the identification : PACTR20210399597082. The study involved 339 patients stricken by Covid-19 with mild to moderate symptoms and has followed Good Clinical Practice (GCP) an international ethical and scientific quality standard for designing, recording and reporting trials that involve the participation of human subjects. The dosage of CURATIVE CVO PLUS is composed of 3 gel caps per day for a duration of 15 days. Each patient was strictly followed during a total of 28 days. The Covid-19 pandemic caused by the “SARS-CoV-2” virus is still propagating in the world despite several anti-covid strategies and notably that of mass vaccination. As of yet there is no single specific medication allowing to cure this disease. In several countries in the world, a race against the clock is underway to vaccinate a large portion of the population in order to prevent further propagation of the virus and at the same time prevent severe forms of the disease. It is also the case for research undertaken to identify curative medications which for the most part are already at the clinical trial stage. Several clinical trial validation steps are needed (phase 1 to 3) before a particular treatment can reach commercialization. In Madagascar, after having consulted the scientific community, the President of Madagascar Andry RAJOELINA has given the approval for research in Covid-19 therapies which are based on Artemisia annua and its derivatives to combat Covid-19. A phase 2 clinical trial was undertaken to evaluate the efficacy of 2 cocktails for the treatment of Covid-19, artesunate injectable and the other protocol consisting of both injectable artesunate and vitamin C. These trials were undertaken from July 2020 and concluded in September 2020. The results of these trials concluded that artesunate injectable taken on its own had a higher efficacy compared to the combination of artesunate and vitamin C.

×